Skip to main content
Logo Logo Logo
  • Investors
    • Investors
    • Stock Information
    • Investors Toolkit
    • Events & Presentations
    • Financial Information
    • SEC Filings
    • Corporate Governance
    • Analyst Coverage
    • Fundamentals
    • Ownership Profile
    • Annual Meetings
    • Press Releases
    • Capella (Scientific Presentations)
    • FAQs
  • Medical Professionals
    • For Medical Professionals
    • Genetic Testing & Counseling
    • Early Access Program
    • Medical Publication Support
    • Investigator Initiated Studies (IIS)
  • Patients
    • For Patients
    • Amyloidosis
    • Acute Hepatic Porphyria
    • Primary Hyperoxaluria
    • Patient Services
    • Genetic Testing and Counseling
    • Patient Advocacy
  • Careers
    • About Careers
    • Working at Alnylam
    • Search Jobs
    • Diversity, Equity & Inclusion
  • Quick Links
    • Clinical Trials
    • Corporate Responsibility
    • Diversity, Equity & Inclusion
    • Press Releases
    • Capella (Scientific Presentations)
    • Medical Resources (RNAi Science)
    • Contact Us
  • Follow Us
    • Youtube
    • Facebook
    • X
    • LinkedIn
    • Instagram
    • Sign Up
  • Global English
    • Austria Deutsch
    • Belgium Nederlands Français
    • Brazil Português
    • Canada Français English
    • Denmark Dansk
    • France Français
    • Germany Deutsch
    • Ireland English
    • Italy Italiano
    • Japan 日本語
    • Luxembourg Français Deutsch
    • Netherlands Nederlands
    • Portugal Português
    • Spain Español
    • Sweden Svenska
    • Switzerland Français Deutsch Italiano
    • Taiwan 繁體中文
    • United Kingdom English
  • Our Company
    • About Alnylam
    • Leadership
    • Diversity, Equity & Inclusion
    • Patient Access Philosophy
    • Corporate Responsibility
    • Alnylam Challengers
    • Transparency
    • Grants & Giving
    • Investigator Initiated Studies (IIS)
  • Our Science
    • The Science of RNAi
    • Delivery Platforms
    • Making Our Medicines
    • Therapeutic Areas
    • Pipeline
    • Clinical Trials
    • Scientific Advisory Board
    • Intellectual Property
    • Capella (Scientific Presentations)
  • Our Products
    • Product Listing
  • Our News
    • Newsroom
    • Press Releases
    • Capella (Scientific Presentations)
    • Media Kit
  • Global English
    • Austria Deutsch
    • Belgium Nederlands Français
    • Brazil Português
    • Canada Français English
    • Denmark Dansk
    • France Français
    • Germany Deutsch
    • Ireland English
    • Italy Italiano
    • Japan 日本語
    • Luxembourg Français Deutsch
    • Netherlands Nederlands
    • Portugal Português
    • Spain Español
    • Sweden Svenska
    • Switzerland Français Deutsch Italiano
    • Taiwan 繁體中文
    • United Kingdom English
  • Our Company
    • About Alnylam
    • Leadership
    • Diversity, Equity & Inclusion
    • Patient Access Philosophy
    • Corporate Responsibility
    • Alnylam Challengers
    • Transparency
    • Grants & Giving
    • Investigator Initiated Studies (IIS)
  • Our Science
    • The Science of RNAi
    • Delivery Platforms
    • Making Our Medicines
    • Therapeutic Areas
    • Pipeline
    • Clinical Trials
    • Scientific Advisory Board
    • Intellectual Property
    • Capella (Scientific Presentations)
  • Our Products
    • Product Listing
  • Our News
    • Newsroom
    • Press Releases
    • Capella (Scientific Presentations)
    • Media Kit
  • Investors

    Investors
    • Investors
    • Stock Information
    • Investors Toolkit
    • Events & Presentations
    • Financial Information
    • SEC Filings
    • Corporate Governance
    • Analyst Coverage
    • Fundamentals
    • Ownership Profile
    • Annual Meetings
    • Press Releases
    • Capella (Scientific Presentations)
    • FAQs
  • Medical Professionals

    Medical Professionals
    • For Medical Professionals
    • Genetic Testing & Counseling
    • Early Access Program
    • Medical Publication Support
    • Investigator Initiated Studies (IIS)
  • Patients

    Patients
    • For Patients
    • Amyloidosis
    • Acute Hepatic Porphyria
    • Primary Hyperoxaluria
    • Patient Services
    • Genetic Testing and Counseling
    • Patient Advocacy
  • Careers

    Careers
    • About Careers
    • Working at Alnylam
    • Search Jobs
    • Diversity, Equity & Inclusion
  • Quick Links

    Quick Links
    • Clinical Trials
    • Corporate Responsibility
    • Diversity, Equity & Inclusion
    • Press Releases
    • Capella (Scientific Presentations)
    • Medical Resources (RNAi Science)
    • Contact Us
  • Follow Us

    Follow Us
    • Youtube
    • Facebook
    • X
    • LinkedIn
    • Instagram
    • Sign Up

Our News

Share this:

Alnylam Challengers: Empowering Frontline Care for Underserved Communities in Boston

November 18, 2025

At Alnylam, we believe that access to quality health care, life-changing medicines, and the support to live healthy, fulfilling lives should be within everyone’s reach. Yet in our hometown of Boston, health outcomes can differ drastically by ZIP code. Most notably, research has shown a life expectancy gap of 23 years between the more affluent neighborhood of Back Bay and the lower-income neighborhood of Roxbury, located just two miles apart.

To help address this challenge, we are investing $2 million to advance the essential work of Boston’s frontline Care Navigators through Alnylam Challengers, our signature global social impact program. We are partnering with three of the city’s most trusted healthcare institutions: Boston Children’s Hospital, Boston Medical Center, and Whittier Street Health Center.

The new partnerships kicked off during Alnylam’s Community Service Week in September, with employees volunteering at the annual Whittier Street Health Fair and providing hygiene and care kits for patients at Boston Medical Center and Boston Children’s Hospital, helping thousands of community members.

Watch the Alnylam Challengers video.

Why Care Navigators?

Care Navigators serve as a vital bridge between clinical care and lasting health and well-being for patients in underserved communities. Often drawing on similar lived experience, they provide personalized coaching, build trust, and connect the hardest-to-reach individuals to essential medical and social services. From helping parents access emergency groceries to connecting families with housing support or transportation to medical appointments, Care Navigators play a crucial role in addressing barriers to care and improving health outcomes.

Research has shown that investments in care navigation deliver strong returns, especially when integrated into care teams serving high-need communities. For example, a review by The Commonwealth Fund of numerous studies evaluating care management models found “higher follow-up visit rates, fewer emergency department visits, reduced Medicaid spending, and reported returns on investment as high as $2.92 for every $1 spent” (The Commonwealth Fund, 2019).

A Collaborative Model for Impact

With this new initiative, Alnylam is investing in four programmatic areas across our nonprofit partners to drive impact:

  1. Hiring Care Navigators and creating cohorts that offer professional training, peer support, and shared resources.
  2. Deploying a Rapid Response Fund that empowers Care Navigators to purchase low-cost, high-impact items that help patients address urgent, time sensitive needs related to transportation, food insecurity, and other non-medical challenges.
  3. Expanding Patient-Centered Programming by investing in one-on-one, customized care navigation and wrap-around health and employment support through community outreach initiatives and education.
  4. Establishing the Challengers Collective to engage nonprofit partner leaders, Care Navigators, and Alnylam employees via working groups and convenings to capture patient insights from the field, advance innovations, and amplify the importance of the Care Navigator role in improving health outcomes.

 

Our employees will also continue to play an important role in supporting Care Navigators and our community partners, leveraging their skills and expertise to support programs, mentor staff, and connect directly with the community.

Together, we aim to create a scalable, community-based model for reducing health disparities in Boston and beyond. A model that ensures every patient feels seen, heard, and supported by removing barriers and delivering high quality, personalized care to those who need it most.

Click here to learn more about Alnylam Challengers, our signature global social impact program, and how we’re investing in communities around the world. We invite you to learn more about our approach to corporate responsibility at Alnylam. 

Tags

Responsibility, Articles, Alnylam Challengers, Health Equity, Corporate Responsibility

Related Content See All News ›
Responsibility Alnylam Recognized by Newsweek as One of America’s Most Responsible Companies for the ...
Responsibility Everest and Everything In Between: A Journey Back to Nepal
Responsibility Supporting Newcomer Entrepreneurs - Forward·Inc’s Challengers Pitch Competition

Share this:

Categories

  • Leadership
  • Perspectives
  • RNAi
  • Patient Focus
  • Responsibility
  • Careers & Culture

Content Types

  • Articles
  • Podcasts
  • Presentations
  • Videos
See All News ›
Related Content See All News ›
Responsibility Alnylam Recognized by Newsweek as One of America’s Most Responsible Companies for the ...
Responsibility Everest and Everything In Between: A Journey Back to Nepal
Responsibility Supporting Newcomer Entrepreneurs - Forward·Inc’s Challengers Pitch Competition
See All News ›

FOLLOW US

Visit our social channels to learn more about the innovative work we are doing at Alnylam.

  • Our Company
  • Our Science
  • Our Products
  • Our News
  • Investors
  • Medical Professionals
  • Patients
  • Job Seekers
  • Clinical Trials
  • Corporate Responsibility
  • Diversity, Equity & Inclusion
  • Press Releases
  • Capella
  • Medical Resources (RNAi Science)
  • Contact Us
  • Sign Up For Updates
  • Privacy Policy
  • Media Kit
  • Legal Notice
  • Site Map
  • Sign Up For Updates

Copyright ©  Alnylam Pharmaceuticals, Inc. — All Rights Reserved

You are now leaving Alnylam.com

The following content may not be associated with Alnylam Pharmaceuticals.

Links to all outside sites are provided as a reference for our visitors.

Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.

Proceed to Site